Non-Hodgkin Lymphoma - Pipeline Review, H2 2020
Non-Hodgkin Lymphoma - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 29, 2, 36, 204, 206, 8, 25, 192, 21 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 28, 34, 3, 37, 6 and 1 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 29, 2, 36, 204, 206, 8, 25, 192, 21 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 28, 34, 3, 37, 6 and 1 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Non-Hodgkin Lymphoma- Overview
Non-Hodgkin Lymphoma- Therapeutics Development
Non-Hodgkin Lymphoma- Therapeutics Assessment
Non-Hodgkin Lymphoma- Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma- Drug Profiles
Non-Hodgkin Lymphoma- Dormant Projects
Non-Hodgkin Lymphoma- Discontinued Products
Non-Hodgkin Lymphoma- Product Development Milestones
Appendix
Non-Hodgkin Lymphoma- Overview
Non-Hodgkin Lymphoma- Therapeutics Development
Non-Hodgkin Lymphoma- Therapeutics Assessment
Non-Hodgkin Lymphoma- Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma- Drug Profiles
Non-Hodgkin Lymphoma- Dormant Projects
Non-Hodgkin Lymphoma- Discontinued Products
Non-Hodgkin Lymphoma- Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2020
Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Abologix Sarl, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ACEA Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Acerta Pharma BV, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Acrotech Biopharma LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adagene Suzhou Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adicet Bio Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adienne Pharma & Biotech, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Advenchen Laboratories LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AGC Biologics SpA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AgenTus Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Agenus Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AI Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Akeso Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aleta Biotherapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alfasigma SpA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Allarity Therapeutics A/S, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alopexx Oncology LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alphamab Oncology, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ALX Oncology Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Anew Oncology Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Angiocrine Bioscience Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Antengene Corp, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AP Biosciences Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Apollomics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Apotex Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Applied Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aprea Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Archigen Biotech Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Argenx SE, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Ascentage Pharma Group International, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AUM Biosciences Pte Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Autolus Therapeutics Plc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Avalon GloboCare Corp, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AVM Biotechnology LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Lupin Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Mablink Bioscience, H2 2020
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2020
Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Abologix Sarl, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ACEA Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Acerta Pharma BV, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Acrotech Biopharma LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adagene Suzhou Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adicet Bio Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adienne Pharma & Biotech, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Advenchen Laboratories LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AGC Biologics SpA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AgenTus Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Agenus Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AI Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Akeso Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aleta Biotherapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alfasigma SpA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Allarity Therapeutics A/S, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alopexx Oncology LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Alphamab Oncology, H2 2020
Non-Hodgkin Lymphoma - Pipeline by ALX Oncology Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Anew Oncology Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Angiocrine Bioscience Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Antengene Corp, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AP Biosciences Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Apollomics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Apotex Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Applied Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aprea Therapeutics Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Archigen Biotech Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Argenx SE, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Ascentage Pharma Group International, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AUM Biosciences Pte Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Autolus Therapeutics Plc, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Avalon GloboCare Corp, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by AVM Biotechnology LLC, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Lupin Ltd, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2020
Non-Hodgkin Lymphoma - Pipeline by Mablink Bioscience, H2 2020
LIST OF FIGURES
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
